{"id":"phase-3b-clozapine-or-another-sgas","safety":{"commonSideEffects":[{"rate":"0.5-1.0","effect":"Agranulocytosis"},{"rate":"10-20","effect":"Weight gain"},{"rate":"20-40","effect":"Sedation"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"10-25","effect":"Tachycardia"},{"rate":"15-30","effect":"Metabolic syndrome"},{"rate":"1-2","effect":"Seizures"},{"rate":"0.1-0.5","effect":"Myocarditis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Second-generation antipsychotics (SGAs) like clozapine antagonize dopamine D2 receptors and serotonin 5-HT2A receptors, reducing hyperactivity in mesolimbic and mesocortical pathways associated with psychosis. Clozapine additionally has activity at multiple other receptors including muscarinic, histaminergic, and adrenergic receptors, which contribute to its efficacy in treatment-resistant schizophrenia and its side effect profile.","oneSentence":"Clozapine and other second-generation antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and improve mood regulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:48.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Treatment-resistant schizophrenia"},{"name":"Bipolar disorder"},{"name":"Psychotic disorders"}]},"trialDetails":[{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1403,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 3B: Clozapine or another SGAs","genericName":"Phase 3B: Clozapine or another SGAs","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clozapine and other second-generation antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and improve mood regulation. Used for Schizophrenia, Treatment-resistant schizophrenia, Bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}